Anti-obesity drug does not produce meaningful weight loss

摘要

An experimental weight loss drug known as MK-0557 is unlikely to be sufficient as monotherapy to treat obesity,the results from a recently published trial suggest(Cell Metabolism 2006;4:275).MK-0557 is a potent,highly selective neuropeptide Y5 receptor antagonist - NPY was one of the first hunger factors identified and the NPY system has long been considered a prime target for anti-obesity drug therapy.